Lumbar Disc Herniation Market is Projected to Reach USD 7.2 Billion by 2036 as Novel Therapies and Minimally Invasive Treatments are Gaining Momentum | DelveInsight

The lumbar disc herniation market is anticipated to increase during the forecast period (2026–2036), owing to the launch of emerging therapies and devices, including STA-363 (Stayable Therapeutics), Triojection (SpinaFX Medical), PerQdisc (Spinal Stabilization Technologies), DISC care (NEOS Surgery), and others, and healthcare spending in the 7MM.

LAS VEGAS, Aug. 4, 2026 /PRNewswire/ -- Recently published Lumbar Disc Herniation Market Insights report includes a comprehensive understanding of current treatment practices, lumbar disc herniation emerging drugs and devices, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Lumbar Disc Herniation Market Summary

• The market size for lumbar disc herniation was found to be USD 27 million in the 7MM in 2025.
• The United States accounted for the largest lumbar disc herniation treatment market size, approximately 42% of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The total number of prevalent cases of lumbar disc herniation in the 7MM was nearly 7.9 million cases in 2025 and is projected to increase during the forecasted period.
• Leading lumbar disc herniation companies, such as Stayable Therapeutics, Seikagaku Corporation, Ferring Pharmaceuticals, SpinaFX Medical, Spinal Stabilization Technologies, NEOS Surgery, and others, are developing new lumbar disc herniation treatment drugs and devices that can be available in the lumbar disc herniation market in the coming years. 
• The promising lumbar disc herniation therapies and devices in clinical trials include STA-363, Condoliase (SI-6603), Triojection, PerQdisc, DISC care, and others.

Discover lumbar disc herniation new treatment @ https://www.delveinsight.com/report-store/lumbar-disc-herniation-market

Key Factors Driving the Growth of the Lumbar Disc Herniation Market 

• Rising Prevalence of Lumbar Disc Herniation and Chronic Low Back Pain: The increasing incidence of lumbar disc herniation, driven by aging populations, sedentary lifestyles, obesity, and occupational strain, is expanding the patient pool. Chronic low back pain remains one of the leading causes of disability worldwide, fueling sustained demand for effective treatment options.
• Advancements in Minimally Invasive Surgical Techniques: Technological innovations such as microdiscectomy, endoscopic spine surgery, and image-guided procedures are improving clinical outcomes while reducing recovery time and hospital stays. These advancements are encouraging greater adoption of surgical treatment among eligible patients.
• Robust Clinical Pipeline and Ongoing Research Activities: Some of the emerging therapies and devices in the lumbar disc herniation pipeline include STA-363 (Stayable Therapeutics), Condoliase (SI-6603) (Seikagaku Corporation/Ferring Pharmaceuticals), Triojection (SpinaFX Medical), PerQdisc (Spinal Stabilization Technologies), DISC care (NEOS Surgery), and others.
• Advancements in AI and Precision Diagnostics: Advances in artificial intelligence, imaging technologies, and predictive analytics are creating opportunities to improve diagnosis, patient stratification, and treatment selection. Personalized treatment algorithms may enhance clinical outcomes by identifying the most appropriate intervention based on individual patient characteristics and disease progression patterns.

Download the report to understand the top emerging lumbar disc herniation devices @ Lumbar Disc Herniation Clinical Trials

Stuti Mahajan, consulting manager at DelveInsight, said that the lumbar disc herniation treatment landscape is expected to evolve toward more personalized and less invasive interventions. Emerging regenerative therapies, innovative decompression procedures, and next-generation spinal implants aim to improve functional outcomes while minimizing recovery time. 

DelveInsight's Lumbar Disc Herniation Market Report delivers executive-level intelligence on the evolving market landscape, integrating epidemiology, treatment practices, competitive dynamics, emerging therapies and devices, and market forecasts across the major markets through 2036. Built on a rigorous methodology combining comprehensive secondary research, primary interviews with key opinion leaders and industry experts, and proprietary patient-based forecasting models, the report provides a reliable foundation for strategic planning. Designed for pharmaceutical and biotech executives, it enables informed decisions on portfolio strategy, business development, market entry, investment prioritization, and commercial planning. 

Lumbar Disc Herniation Market Analysis

• The current treatment paradigm for lumbar disc herniation includes conservative care, pharmacological management, minimally invasive procedures, and surgical interventions, with therapeutic decisions guided by symptom intensity, neurological impairment, and patient response to initial treatment. 
• Conservative therapy remains the preferred first-line strategy and typically consists of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, muscle relaxants, brief corticosteroid regimens, physical therapy, lifestyle modifications, and activity adjustment. These approaches successfully alleviate symptoms in a substantial proportion of patients. 
• Although clinical management strategies have advanced considerably, pharmacological options remain limited because existing medications primarily focus on symptom control rather than addressing the underlying disc degeneration. 
• Condoliase (SI-6603), developed by Seikagaku Corporation, is currently the only approved drug specifically indicated for LDH. Approved in Japan, it is administered as a single intradiscal injection that lowers intradiscal pressure by selectively degrading glycosaminoglycans within the nucleus pulposus. 
• While Condoliase has demonstrated significant clinical efficacy and offers a minimally invasive alternative to surgery, no pharmacological therapies have yet been approved for LDH in either the United States or Europe, where management continues to rely on conservative treatment, interventional pain procedures, and surgical intervention. 
• Nevertheless, the development pipeline is progressing, with Stayble Therapeutics' STA363 emerging as a promising investigational intradiscal therapy intended to induce localized fibrosis and deliver durable pain relief following a single injection.
• In parallel with pharmaceutical innovation, advances in medical devices and minimally invasive technologies are reshaping the LDH treatment landscape. 
• Commercially available solutions include hydrodiscectomy systems such as SpineJet PercResector and MicroResector; endoscopic platforms including iLESSYS Biportal, TESSYS, VERTEBRIS, WishBone, and SPINETIP; laser-assisted decompression technologies based on PLDD platforms; percutaneous discectomy devices such as Dekompressor, NUCLEOTOME, SpineWand, DISKOM, HERNIATOME, Disc-FX, and MaxDisc; annular closure systems including the FDA-approved BARRICAID; non-invasive spinal decompression technologies; and minimally invasive surgical instruments such as the CONCORDE Clear MIS Discectomy Device. 
• The emerging device pipeline is also expanding, led by TrioInjection from SpinaFX Medical, which has secured FDA Breakthrough Device Designation and Investigational Device Exemption (IDE) approval for pivotal clinical studies, along with DISC care from NEOS Surgery, an investigational annular closure implant developed to lower the risk of recurrent disc herniation. 
• Overall, while conservative management and microdiscectomy remain the established standards of care worldwide, future LDH treatment is expected to increasingly incorporate minimally invasive biologic therapies, regenerative medicine, and next-generation intradiscal technologies, to reduce reliance on surgery and improve long-term clinical outcomes.

Lumbar Disc Herniation Competitive Landscape

Some of the emerging lumbar disc herniation drugs and devices under development include STA-363 (Stayable Therapeutics), Condoliase (SI-6603) (Seikagaku Corporation/Ferring Pharmaceuticals), Triojection (SpinaFX Medical), PerQdisc (Spinal Stabilization Technologies), DISC care (NEOS Surgery), and others.

Stayable Therapeutics' STA363 is an investigational, locally administered, single-injection therapy being developed as a disease-modifying treatment for lumbar disc herniation (LDH). It is intended to decrease disc volume, ease nerve compression, and target the underlying biological mechanisms responsible for pain. Positioned as a non-surgical, second-line option for patients who experience insufficient symptom relief from physiotherapy or analgesic medications, STA363 is supported by patent protection through 2041, with the possibility of patent term extensions in the US and other regions extending exclusivity to 2046. The therapy is currently undergoing Phase I clinical development for the treatment of LDH.

SpinaFX's TrioInjection (Triojection Oxygen-Ozone Therapy) is a minimally invasive intradiscal treatment designed for patients with symptomatic lumbar disc herniation accompanied by radicular pain who have not achieved adequate improvement with conservative therapies. The procedure utilizes image-guided delivery of a medical oxygen–ozone mixture directly into the affected intervertebral disc, helping reduce disc volume and intradiscal pressure while relieving nerve root compression. In addition, the therapy offers anti-inflammatory and analgesic benefits. Performed under local anesthesia in an outpatient setting, the procedure promotes faster recovery, minimizes tissue damage, and reduces the need for hospital resources. 

Clinical evidence has demonstrated meaningful improvements in pain relief and functional recovery, with outcomes in appropriately selected patients approaching those of surgical intervention, enabling many individuals to avoid more invasive procedures. Consequently, TrioInjection™ is gaining recognition as an effective treatment option that bridges the gap between unsuccessful conservative management and surgery for contained lumbar disc herniation.

The anticipated launch of these emerging therapies and devices are poised to transform the lumbar disc herniation market landscape in the coming years. As these cutting-edge therapies and devices continue to mature and gain regulatory approval, they are expected to reshape the lumbar disc herniation market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about which pipeline drugs could transform lumbar disc herniation treatment @ Lumbar Disc Herniation Medicaltions

Recent Developments in the Lumbar Disc Herniation Market

• In June 2026, SpinaFX Medical announced that the FDA granted an Investigational Device Exemption (IDE) for Triojection, allowing the initiation of a pivotal US clinical trial.
• In March 2026, Intrinsic Therapeutics introduced the Barricaid® Narrow Anchor, the next generation of its FDA PMA-approved Barricaid® Bone-Anchored Annular Closure Device. The new version of the Barricaid device is 25 percent smaller than the standard Barricaid anchor.
• In March 2026, Seikagaku Corporation announced the resubmission of the BLA for Condoliase (SI-6603) to the US FDA for the treatment of Lumbar Disc Herniation, addressing issues raised in the previous Complete Response Letter and seeking regulatory approval in the United States.
• In August 2025, Triojection received FDA Breakthrough Device Designation, recognizing its potential to provide a safer and more effective treatment option for patients with contained lumbar disc herniations.

Lumbar Disc Herniation Epidemiology Segmentation

The lumbar disc herniation epidemiology section provides insights into the historical and current lumbar disc herniation patient pool and forecasted trends for the leading markets. The total number of prevalent cases of lumbar disc herniation in the United States was nearly 3.3 million cases in 2025.

The lumbar disc herniation treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of Lumbar Disc Herniation
• Total Diagnosed Prevalent Cases of Lumbar Disc Herniation
• Age-specific Cases of Lumbar Disc Herniation
• Gender-specific Cases of Lumbar Disc Herniation 
• Location-specific Cases of Lumbar Disc Herniation

Scope of the Lumbar Disc Herniation Market Report

• Lumbar Disc Herniation Patient Population Forecast
• Lumbar Disc Herniation Therapeutics Market Size
• Lumbar Disc Herniation Pipeline Analysis
• Lumbar Disc Herniation Market Size and Trends
• Lumbar Disc Herniation Market Opportunity
• Lumbar Disc Herniation Market Unmet Needs
• KOL's Views on Lumbar Disc Herniation
• Lumbar Disc Herniation Market Access and Reimbursement

Table of Contents

Related Reports

Lumbar Degenerative Disc Disease Market

Lumbar Degenerative Disc Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key lumbar degenerative disc disease companies, including Spine BioPharma Inc, MCRA, Synthes USA HQ Inc, NuVasive, Globus Medical Inc, Spineology Inc, Ranier Technology Limited, DiscGenic Inc, Invibio Ltd, Yuhan Corporation, Orthofix Inc, Janssen Korea Ltd, Eisai, Globus Medical Inc, Apatech Inc., Orthofix Inc, Bone Therapeutics S.A., and others.

Degenerative Disc Disease Market

Degenerative Disc Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key lumbar degenerative disc disease companies, including Spine Biopharma, DiscGenics, Mesoblast, Grünenthal, AnGes, BioRestorative Therapies, Kolon TissueGene, Citospin, Creative Medical Technology, and others.

Spinal Cord Injury Market

Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SCI companies, including Nipro Corporation, Kringle Pharma, Neuroplast, Mitsubishi Tanabe Pharma America, AbbVie, BioCT, and others.

Sciatica Market

Sciatica Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sciatica companies, including Sollis Therapeutics, Scilex Holding, Eliem Therapeutics, Breath of Life International Pharma Ltd, Kolon Life Science, SPINETHERA, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com 

+14699457679

www.delveinsight.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumbar-disc-herniation-market-is-projected-to-reach-usd-7-2-billion-by-2036-as-novel-therapies-and-minimally-invasive-treatments-are-gaining-momentum--delveinsight-302842013.html

SOURCE DelveInsight Business Research, LLP